Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Breakthrough infection

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44343   clinical trials with a EudraCT protocol, of which   7372   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    113 result(s) found for: Breakthrough infection. Displaying page 1 of 6.
    1  2  3  4  5  6  Next»
    EudraCT Number: 2021-006832-24 Sponsor Protocol Number: Z-2021005 Start Date*: 2022-01-21
    Sponsor Name:Ziekenhuis Oost-Limburg A.V.
    Full Title: Heterogeneity, durability and efficacy of the humoral immune response against SARS-CoV-2 (Covid-19) after hospital-wide vaccination
    Medical condition: efficiency and durability of the humoral immune response after vaccination against SARS-CoV-2
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-002800-40 Sponsor Protocol Number: A1501073 Start Date*: 2006-02-09
    Sponsor Name:Pfizer Ltd
    Full Title: Prospective, Open-label, Comparative, Multicenter Study of Voriconazole Compared to Itraconazole for the Primary Prophylaxis of Invasive Fungal Infections (IFI) in Subjects with Allogeneic Hematopo...
    Medical condition: Prophylaxis against invasive fungal infection following allogeneic hematopoietic stem cell transplantation.
    Disease: Version SOC Term Classification Code Term Level
    8 10017533
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) CZ (Completed) ES (Completed) PT (Completed) GR (Completed)
    Trial results: View results
    EudraCT Number: 2004-000501-21 Sponsor Protocol Number: 2003-12 Start Date*: 2005-04-30
    Sponsor Name:XTL Biopharmaceuticals
    Full Title: A Phase II, Multicenter, Randomized, Open-Label, Dose-Ranging, Parallel Group Study to Compare the Anti-Viral Effects, Pharmacokinetics and Safety of HepeX-B, a Mixture of Two Monoclonal Antibodies...
    Medical condition: Hepatic allograft recipients for treatment of hepatitis B virus infection.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2021-000386-32 Sponsor Protocol Number: F901318/0041 Start Date*: 2022-01-21
    Sponsor Name:F2G Ltd.
    Full Title: A Phase III, adjudicator-blinded, randomised study to evaluate the efficacy and safety of treatment with olorofim versus treatment with AmBisome® followed by standard of care (SOC) in patients with...
    Medical condition: invasive fungal infections due to Aspergillus spp.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) FR (Trial now transitioned) BE (Trial now transitioned) NL (Trial now transitioned) IT (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2012-003172-39 Sponsor Protocol Number: Mica1/2012 Start Date*: 2013-05-23
    Sponsor Name:Medizinische Universität Innsbruck, Abteilung für Hygiene und Medizinische Mikrobiologie
    Full Title: Micafungin-Deescaltion study: Evalutating the rate of breakthrough infections of micafungin followed by fluconazole versus fluconazole (or other azoles) in febrile patients
    Medical condition: All patients who are suspicious of suffering from invasive fungal infections are included.
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004274-87 Sponsor Protocol Number: NV-02B-022 / CLDT600A2303 Start Date*: 2005-09-30
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies
    Medical condition: chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    9.1 10008910 Chronic hepatitis B LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) GB (Completed) ES (Completed) CZ (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2016-001444-20 Sponsor Protocol Number: CLDT600ACN03 Start Date*: 2016-05-18
    Sponsor Name:Beijing Novartis Pharma Co., Ltd.
    Full Title: An Open-label, Single-arm, Multicenter, Phase IV, 52-week Study to Evaluate the Efficacy and Safety of Telbivudine 600mg Tablets in Chinese Patients with Chronic Hepatitis B
    Medical condition: chronic hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2021-001304-15 Sponsor Protocol Number: AZGS2021005 Start Date*: 2021-05-06
    Sponsor Name:vzw az groeninge
    Full Title: COVID-19: Study of the immune response in healthy volunteers after vaccination against SARS-CoV-2 (COVID19-VAX-AZG) and monitoring of breakthrough infections after booster vaccination (COVID19-VAX-...
    Medical condition: immuneresponse after vaccination
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000944-43 Sponsor Protocol Number: GS-US-248-0120 Start Date*: 2011-08-09
    Sponsor Name:Gilead Sciences Inc.
    Full Title: A Phase 2 Randomized, Open-Label Study of GS-5885 Administered Concomitantly with GS-9451, Tegobuvir and Ribavirin (RBV) to Treatment-Naive Subjects with Chronic Genotype 1 HCV Infection
    Medical condition: Genotype 1 Hepatitis C Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    14.0 10021881 - Infections and infestations 10021881 Infections and infestations SOC
    14.0 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2021-003573-58 Sponsor Protocol Number: 2025 Start Date*: 2021-08-09
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancEr: booster shot BNT161b2 vaccine after full vaccination with ChAdOx1-S vaccine (Tri-VOICE plus)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000300-38 Sponsor Protocol Number: 001610 Start Date*: 2021-02-05
    Sponsor Name:Antwerp University Hospital
    Full Title: Vaccination against cOvid-19 In CancER patients under active treatment (Belgium, B-VOICE)
    Medical condition: Onco-hematological patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-005132-33 Sponsor Protocol Number: 73763989PAHPB2008 Start Date*: 2022-04-11
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Open-label Trial to Evaluate Safety, Efficacy, Tolerability, and Pharmacodynamics of a Combination of JNJ-73763989, Nucleos(t)ide Analogs, and a PD-1 inhibitor in Chronic Hepatitis B Pati...
    Medical condition: Chronic Hepatitis B Virus Infection
    Disease: Version SOC Term Classification Code Term Level
    20.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults Gender: Male, Female
    Trial protocol: FR (Completed) ES (Ongoing) IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-000461-33 Sponsor Protocol Number: P2020_312 Start Date*: 2021-02-17
    Sponsor Name:Hopital Erasme, Université Libre de Bruxelles
    Full Title: Covid-19: Sars-Cov2 vaccination in hemodialysis patient: a phase IV study of the immunogenicity and its determinants
    Medical condition: Chronic hemodialysis patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2021-000412-28 Sponsor Protocol Number: P2020_284 Start Date*: 2021-02-17
    Sponsor Name:Hopital Erasme, Université Libre de Bruxelles
    Full Title: COVID-19: Sars-Cov2 vaccination in kidney transplant patient: a phase IV study of the immunogenicity and its determinants
    Medical condition: Kidney transplant patients
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000416-25 Sponsor Protocol Number: TMC435-TiDP16-C213 Start Date*: 2011-09-02
    Sponsor Name:Janssen R&D Ireland
    Full Title: A Phase III, open-label trial of TMC435 in combination with peginterferon alpha-2a and ribavirin for HCV genotype-1 infected subjects who participated in the placebo group of a Phase II/III TMC435 ...
    Medical condition: Hepatitis C Virus (HCV) genotype-1 infection
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10019744 Hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) GB (Completed) ES (Completed) AT (Completed) PT (Completed) NL (Completed) DE (Completed) PL (Completed) BG (Completed)
    Trial results: View results
    EudraCT Number: 2009-016560-36 Sponsor Protocol Number: NV22688 Start Date*: 2010-07-27
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A long-term monitoring study to evaluate the persistence of direct acting antiviral (DAA) treatment-resistant mutations or the durability of sustained virological response (SVR) in patients treated...
    Medical condition: Chronic Hepatitis C
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10008912 Chronic hepatitis C PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) IT (Prematurely Ended) AT (Prematurely Ended) ES (Completed) PL (Prematurely Ended) SK (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2016-002271-97 Sponsor Protocol Number: F901318C21 Start Date*: 2017-04-07
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of oral F901318 (combined with fluconazole and posaconazole) for antifungal prophylaxis in patients undergoing che...
    Medical condition: Invasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.1 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2016-000919-33 Sponsor Protocol Number: F901318C20 Start Date*: 2016-10-12
    Sponsor Name:F2G Limited
    Full Title: An open label phase IIa clinical study to evaluate the safety and pharmacokinetics of intravenous and oral F901318 (combined with caspofungin) for antifungal prophylaxis in patients undergoing chem...
    Medical condition: Infasive fungal disease in patients with acute myeloid leukemia under chemotherapy
    Disease: Version SOC Term Classification Code Term Level
    19.0 10021881 - Infections and infestations 10017533 Fungal infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2014-001011-39 Sponsor Protocol Number: GS-US-330-1401 Start Date*: 2015-03-26
    Sponsor Name:Gilead Sciences, Inc.
    Full Title: A Phase 2, Randomized, Open-Label Study to Evaluate the Safety and Efficacy of GS-4774 in combination with Tenofovir Disoproxil Fumarate (TDF) for the Treatment of Subjects with Chronic Hepatitis B...
    Medical condition: Chronic Hepatitis B
    Disease: Version SOC Term Classification Code Term Level
    17.1 10021881 - Infections and infestations 10008910 Chronic hepatitis B PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: View results
    EudraCT Number: 2021-003188-90 Sponsor Protocol Number: ENFORCE-PLUS Start Date*: 2021-07-01
    Sponsor Name:CHIP - Rigshospitalet - University of Copenhagen
    Full Title: A Phase IV Vaccine Study under the National Cohort Study of Effectiveness and Safety of SARS-CoV-2/Covid-19 vaccines (ENFORCE PLUS)
    Medical condition: The primary objective of the study is to assess if the SARS-CoV-2 vaccine Johnson & Johnson/Janssen results in change in number and activation of platelets and anti-PF4 level. As well as to compare...
    Disease: Version SOC Term Classification Code Term Level
    23.1 100000004865 10084465 COVID-19 vaccination LLT
    Population Age: Adults Gender: Male, Female
    Trial protocol: DK (Prematurely Ended)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  Next»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Jun 14 10:12:34 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA